Thursday, September 17
11:20 am Conference Registration for Part B Programs
12:20 pm Event Chairperson's Opening Remarks
An-Dinh Nguyen, Team Lead, Discovery on Target 2020, Cambridge Healthtech Institute
12:30 Plenary Keynote Introduction (Sponsorship Opportunity Available)
Tackling Undruggable Oncoproteins: Lessons from the VHL Tumor Suppressor Protein
William G. Kaelin, Jr., MD, Professor and Investigator, Howard Hughes Medical Institute, Oncology, Dana-Farber Cancer Institute
VHL tumor suppressor protein (pVHL) inactivation is common in kidney cancer and upregulates the HIF2 transcription factor. PT2977/MK-6482 is an allosteric HIF2 inhibitor now in Phase 3 testing. Thalidomide-like drugs (IMiDs) bind to cereblon which, like pVHL, is the substrate-binding unit of a ubiquitin ligase. IMiDs redirect cereblon to destroy the myeloma oncoproteins, IKZF1 and IKZF3. We have developed new assays for identifying drugs that can destabilize oncoproteins of interest.
1:20 KEYNOTE PANEL DISCUSSION:
De-Risking Early Drug Discovery
Nadeem Sarwar, PhD, Founder & President, Eisai Center for Genetics Guided Dementia Discovery, Eisai, Inc.
- Data Sciences
- Novel Chemical Modalities
- Investment and Partnering Models
- COVID-19 Progress as Examples of Successful Partnerships
Anthony A. Philippakis, PhD, Chief Data Officer, Data Sciences & Data Engineering, Broad Institute; Venture Partner, GV
Andrew Plump, MD, PhD, President, Research & Development, Takeda Pharmaceuticals, Inc.
2:00 Close of Plenary Keynote Program
2:00 Dessert Break in the Exhibit Hall with Poster Viewing
2:45 Organizer's Welcome Remarks
Cambridge Healthtech Institute
2:50 Chairperson's Remarks
Cory M. Hogaboam, PhD, Professor, Medicine, Cedars-Sinai Medical Center
Small-Molecule Inhibitors Targeting Nox4 for the Treatment of Lung Fibrosis
Louise Hecker, PhD, Assistant Professor, Medicine, University of Arizona
Cell-Specific Roles of Integrin Alpha V in Inflammation and Fibrosis
Kevin Hart, PhD, Principal Scientist, Inflammation, Pfizer Inc.
Integrin-alpha V serves as a master driver of fibroproliferative diseases in multiple organs. We investigated roles for integrin-alpha V interactions on fibroblasts and cholangiocytes and defined novel roles for cell-specific expression of ITGAV in the regulation of inflammatory responses and in driving microenvironmental fibrogenesis.
Xylyx IN MATRICOTM Fibrosis Assay Platform is a standardized fibrosis model that recapitulates the fibrosis disease environment using intact human fibrotic ECM, as well as patient-specific clinical data corresponding to the human tissue ECM substrates, enabling compound testing assays in diseased human ECM.
4:10 Sponsored Presentation (Opportunity Available)
4:25 Refreshment Break in the Exhibit Hall with Poster Viewing
ROCK Updates and New Fibrosis Targets
Masha Poyurovsky, PhD, Vice President, Discovery Biology, Kadmon Corporation
Molecular mechanisms linking changes in the mechanical environment during injury, repair, and fibrosis to cellular activation, regulate transient and persistent alterations that contribute to fibrosis. Kadmon will present data on two regulators of these mechanisms. ROCK, an intracellular regulator, integrating mechanical stress, biochemical signals, and activation of transcription of fibrotic ECM and CCN1, a matricellular protein, strongly induced at the sites on injury and fibrosis.
Inhibition of Dimeric Calpains Results in Reduction of Lung and Liver Fibrosis
Maria E. Fuentes, PhD, Executive Vice President, Research, Blade Therapeutics
Calpains are non-lysosomal, calcium-activated cysteine proteases that play multiple roles in a wide range of cell types. A subgroup of this calpain family, dimeric calpains (CAPN1, 2 and 9), have been shown to play a role in fibrotic disease models. Blade Therapeutics has developed selective calpain inhibitors that are active at inhibiting collagen production in in vitro systems and they reduce lung and liver fibrosis in vivo.
Caveolin, a New IPF Target
Brian Windsor, PhD, CEO, Lung Therapeutics
6:30 Dinner Short Course Registration (Premium Package or separate registration required)
7:00 Dinner Short Courses 10-12 (see Short Courses page for details)
9:30 Close of Day
Friday, September 18
7:00 am Registration
7:30 Interactive Breakfast Breakout Discussion Groups
Grab a cup of coffee and join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Visit the conference website for discussion topics and moderators.
8:30 Transition to Sessions
8:40 Chairperson's Remarks
John O’Neill, CSO, Xylyx Bio, Inc.
Targeting Integrins for Lung and Other Organ Fibrosis
Scott M. Turner, PhD, Vice President, Translational Sciences, Pliant Therapeutics
Characterization of IDL-2965, a Clinical-Stage Integrin Antagonist for the Treatment of IPF
Karl J. Kossen, PhD, Senior Vice President, Translational Science, Indalo Therapeutics
Targeting Autotaxin for Treating Idiopathic Pulmonary Fibrosis (IPF)
Gwanghee Lee, PhD, Senior Vice President, Translational Research, Bridge Biotherapeutics Inc.
10:15 Coffee Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced
Translational Pharmacology of TD139, an Inhaled Small-Molecule Galectin-3 Inhibitor for the Treatment of IPF
Rob Slack, PhD, Director of Pharmacology, Galecto, Inc.
Galectin-3 is a ß-galactoside-binding lectin highly expressed in fibrotic tissue of diverse etiologies and has been shown to play a key role in organ fibrosis. Galecto, Inc. has developed a number of high-affinity and selective galectin-3 inhibitors currently undergoing clinical investigation in fibrotic diseases of the lung and liver. This talk will focus on the translational pharmacology of these galectin-3 inhibitors and their potential as anti-fibrotic therapies.
Clinical Compounds for and against NOX4 for Targeting Fibrosis
Elias Papatheodorou, Chief Business Officer, GenkyoTex SA
11:55 Sponsored Presentation (Opportunity Available)
12:25 Session Break
12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:05 Refreshment Break in the Exhibit Hall with Poster Viewing
1:50 Chairperson's Remarks
Vanessa M. Morales-Tirado, PhD, Principal Research Scientist I, Translational Immunology, AbbVie Bioresearch Center
Translational Trends in Fibrosis Drug Discovery
Carolyn Cuff, PhD, Lead, Translational Immunology & Discovery R&D, AbbVie
Humanized IPF Mouse Models
Cory M. Hogaboam, PhD, Professor, Medicine, Cedars-Sinai Medical Center
Initiated by the intravenous injection of cells from IPF lung biopsy or explants into SCID mouse strains, IPF cells promote persistent, non-resolving, lung remodeling in SCID mice, unlike cells from normal lung samples. Potential advantages and pitfalls of human-specific targeting approaches in a humanized SCID model of pulmonary fibrosis will also be addressed.
2:55 KEYNOTE PRESENTATION:
From Genes to Mechanisms to Medicines: The Arc of Discovery for Fibrotic Diseases
Anna Greka, MD, PhD, Associate Professor of Medicine, BWH/Harvard Medical School/Broad Institute
3:25 Talk Title to be Announced
Ji Zhang, PhD, Scientist, Cardiorenal Metabolic & Ophthalmologic Drug Discovery, Merck Research Labs
3:55 Close of Conference